【摘要】：背景與目的:人附睪蛋白4(human epididymis protein 4,HE4)是一種新型上皮性卵巢癌(epithelial ovarian cancer,EOC)的血清免疫標(biāo)志物。本研究旨在評(píng)價(jià)其與卵巢最常用的血清標(biāo)志物—糖類抗原125(cancer antigen-125,CA125)和腹、盆腔CT/MRI檢查對(duì)卵巢癌術(shù)后復(fù)發(fā)的診斷價(jià)值。方法:回顧性分析EOC術(shù)后復(fù)發(fā)患者92例,其中二次手術(shù)48例,化療44例。統(tǒng)計(jì)治療前血清CA125、HE4和腹、盆腔CT/MRI檢查診斷的靈敏度,并與手術(shù)病理和臨床隨訪結(jié)果進(jìn)行對(duì)照。結(jié)果:血清CA125和HE4的靈敏度分別為58.7%和61.9%。兩者差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);聯(lián)合兩者的靈敏度為80.4%,較單一應(yīng)用顯著提高(P0.05)。腹、盆腔CT/MRI的靈敏度為88.0%,顯著高于血清CA125和HE4(P0.01)。與兩者聯(lián)用相比,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。三者聯(lián)合應(yīng)用的靈敏度最高(97.8%),顯著高于血清CA125和HE4聯(lián)用(P0.01),以及單用腹、盆腔CT/MRI(P0.05)。結(jié)論:血清HE4對(duì)于EOC術(shù)后復(fù)發(fā)的檢出與CA125同樣有效,兩者聯(lián)合應(yīng)用可顯著提高診斷的靈敏度。與腹、盆腔影像學(xué)檢查三者聯(lián)用的靈敏度最高,是EOC術(shù)后監(jiān)測(cè)較佳的策略。
[Abstract]:Background & AIM: human epididymal protein 4 (human epididymis protein 4 (HE4) is a novel serum immunomarker for epithelial ovarian cancer (epithelial ovarian cancer,EOC). The purpose of this study was to evaluate the diagnostic value of serum antigens 125 (cancer antigen-125,CA125) and abdominal and pelvic CT/MRI in the diagnosis of postoperative recurrence of ovarian cancer. Methods: 92 cases of recurrence after EOC were analyzed retrospectively, including 48 cases of secondary operation and 44 cases of chemotherapy. The diagnostic sensitivity of serum CA125,HE4, abdominal and pelvic CT/MRI before treatment was statistically analyzed and compared with the results of surgical pathology and clinical follow-up. Results: the sensitivity of serum CA125 and HE4 were 58.7% and 61.9%, respectively. There was no significant difference between the two groups (P0.05), and the sensitivity of combination was 80.4, which was significantly higher than that of single application (P0.05). The sensitivity of abdominal and pelvic CT/MRI was 88.0 and significantly higher than that of serum CA125 and HE4 (P0.01). There was no significant difference between the two groups (P0.05). The sensitivity of the combined treatment was the highest (97.8%), which was significantly higher than the combination of serum CA125 and HE4 (P0.01), and the single use of abdominal and pelvic CT/MRI (P0.05). Conclusion: serum HE4 is as effective as CA125 in detecting recurrence after EOC. In combination with abdominal and pelvic imaging, the sensitivity of these three methods is the highest and is a better strategy for monitoring after EOC.
【作者單位】： 上海市第八人民醫(yī)院婦產(chǎn)科;復(fù)旦大學(xué)附屬腫瘤醫(yī)院婦瘤科復(fù)旦大學(xué)上海醫(yī)學(xué)院腫瘤學(xué)系;復(fù)旦大學(xué)附屬腫瘤醫(yī)院放射診斷科復(fù)旦大學(xué)上海醫(yī)學(xué)院腫瘤學(xué)系;
【分類號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前9條

1 李孟達(dá),李玉潔,黃永文,黃鶴;影響上皮性卵巢癌遠(yuǎn)期療效的因素分析[J];癌癥;2004年11期

2 胡同秀;范社華;馬媛;;腫瘤標(biāo)記物及凝血功能檢測(cè)在卵巢癌鑒別診斷中意義[J];中華實(shí)用診斷與治療雜志;2010年11期

3 程燕;寧剛;宋彬;朱慧莉;趙福敏;鮑莉;羅小華;;卵巢癌術(shù)后復(fù)發(fā)及腹膜轉(zhuǎn)移的多排螺旋CT表現(xiàn)及其與血清CA125的關(guān)系[J];四川大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2007年04期

4 宋曉翠;張文s，

本文編號(hào)：2353734